

- **Name:** Jae Lyun Lee
  - **Current Position & Affiliation:** Professor, Department of Oncology, University of Ulsan College of Medicine.  
Director of Genitourinary Cancer Center, Asan Cancer Hospital.
  - **Country:** Korea
- 

• **Educational Background:**

1. Philosophy Doctor from Ulsan University Graduate School of Medicine (2007)
2. Master of Medical Science from Yeungnam University Graduate School of Medicine (2005)
3. Bachelor of Medical science (Medical Doctor degree) from Yeungnam University School of Medicine (1993)

• **Professional Experience:**

1. Mar 2024 ~, Director of Genitourinary Cancer Center, Asan Cancer Hospital
2. Mar 2022 ~, Chair of Healthcare Insurance and Policy Committee, KSMO
3. Feb 2019 ~ Mar 2023, Chairperson of Genitourinary Cancer Committee, Korean Cancer Study Group (KCSG)
4. Jan 2019 ~, ESMO Faculty, GU Cancer
5. Mar 2017 ~ . Professor, Department of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
6. April 2009 ~ June 2010, Visiting professor, Genitourinary Disease-Oriented Working Group and Phase I Program, UW Carbone Cancer Center, Madison, WI, USA.
7. Mar 2011 ~ Mar 2017. Associate professor, Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
8. Mar 2004 ~ Feb 2011. Assistant professor, Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
9. March 2003 – Aug 2004. Full-time instructor of Oncology-Hematology, Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea

• **Professional Organizations:**

KSMO, KCA, KCSG, KUOS, ASCO, AACR, ESMO, SITC

**• Main Scientific Publications:**

1. A Multicenter Phase II Study of Modified FOLFIRINOX for First-line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03). Park I, Lee JL, Yoon S, Shin SJ, Shin SH, Kim JH, Park K, Lee HJ. Cancer Res Treat. 2025
2. Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-line Platinum-based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05). Park I, Yoon S, Kim I, Park K, Lee S, Keam B, Park JH, Kim JY, Choi YJ, Sohn BS, Lee JL. Cancer Res Treat. 2024
3. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. Choueiri TK et al. N Engl J Med. 2024
4. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Kelly WK et al. Cancer Discov. 2024
5. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. Choueiri TK, et al. N Engl J Med. 2024
6. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Albiges L, et al. Lancet Oncol. 2023
7. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Choueiri TK, et al. N Engl J Med. 2021
8. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. Powles T, et al. N Engl J Med. 2021